Detalhe da pesquisa
1.
Acyloxyacyl hydrolase promotes pulmonary defense by preventing alveolar macrophage tolerance.
PLoS Pathog
; 19(7): e1011556, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37498977
2.
Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.
BMC Cancer
; 24(1): 715, 2024 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38862908
3.
Special issue "The advance of solid tumor research in China": Real-world clinical outcomes of alectinib for advanced nonsmall-cell lung cancer patients with ALK fusion in China.
Int J Cancer
; 152(1): 15-23, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35579989
4.
Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study.
Cancer Immunol Immunother
; 71(7): 1625-1631, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34743223
5.
Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
BMC Cancer
; 22(1): 294, 2022 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35305596
6.
Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update.
Chin J Cancer Res
; 34(1): 28-39, 2022 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35355930
7.
Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
Respir Res
; 22(1): 145, 2021 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33975616
8.
Serum TNFRII: A promising biomarker for predicting the risk of subcentimetre lung adenocarcinoma.
J Cell Mol Med
; 24(7): 4150-4156, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32073741
9.
Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies.
Int J Cancer
; 146(11): 3124-3133, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31583695
10.
Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy.
Eur Respir J
; 53(3)2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30578392
11.
Acyloxyacyl hydrolase promotes the resolution of lipopolysaccharide-induced acute lung injury.
PLoS Pathog
; 13(6): e1006436, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28622363
12.
Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete Lobectomy.
Ann Surg Oncol
; 26(8): 2392-2400, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31011907
13.
Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial.
Int J Cancer
; 141(6): 1249-1256, 2017 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28560853
14.
RAD18 polymorphisms are associated with platinum-based chemotherapy toxicity in Chinese patients with non-small cell lung cancer.
Acta Pharmacol Sin
; 37(11): 1490-1498, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27665847
15.
Lung cancer-derived Dickkopf1 is associated with bone metastasis and the mechanism involves the inhibition of osteoblast differentiation.
Biochem Biophys Res Commun
; 443(3): 962-8, 2014 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24361889
16.
Epidermal growth factor induces FoxO1 nuclear exclusion to activate MMP7-mediated metastasis of larynx carcinoma.
Tumour Biol
; 35(10): 9987-92, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25008564
17.
Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations.
Front Oncol
; 14: 1357231, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38567147
18.
Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial.
Cancer Biol Med
; 2024 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38809003
19.
EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.
Target Oncol
; 19(2): 277-288, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38416376
20.
Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer.
J Immunother Cancer
; 12(4)2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38641349